G6PC1抗体—艾普蒂 新品

+ +

•  

   

     All lanes : Anti-Enpp1 Antibody (N-term) at 1:1000 dilution Lane 1: Hela whole cell lysate Lane 2: mouse bladder lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 103 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

  
  

**Background of G6PC1 Antibodies**

G6PC1 (glucose-6-phosphatase catalytic subunit 1) is a key enzyme in glucose homeostasis, primarily expressed in the liver and kidney. It catalyzes the final step of gluconeogenesis and glycogenolysis by hydrolyzing glucose-6-phosphate to glucose, enabling its release into the bloodstream. Dysregulation of G6PC1 is linked to metabolic disorders, including type 1a glycogen storage disease (GSD1a, von Gierke disease), caused by G6PC1 mutations that impair enzymatic activity, leading to severe hypoglycemia and hepatic complications.

Antibodies targeting G6PC1 are essential tools for studying its expression, localization, and function in metabolic pathways. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate tissue-specific G6PC1 activity, particularly in liver and kidney samples. Additionally, these antibodies aid in research on diabetes, insulin resistance, and hepatocellular carcinoma, where altered gluconeogenesis is implicated.

Commercial G6PC1 antibodies are typically raised in rabbits or mice against specific epitopes of the human or murine protein. Validation includes testing for cross-reactivity with related isoforms (e.g., G6PC2. G6PC3) and confirming specificity using knockout models or siRNA-mediated silencing. Reliable G6PC1 antibodies are critical for advancing understanding of metabolic diseases and developing targeted therapies.